- ProSense is gaining commercial traction in Europe where it has CE approval for numerous
malignant and benign tissue indications.
- Symposium presenters include Professor Francois Cornelis who used ProSense in an
endometriosis study which demonstrated cryoablation's efficacy rate
of 92.8% in avoiding secondary surgery and Professor Julien Frandon who conducted a feasibility study
of ProSense with positive results in kidney, bone, liver, lung, and
soft tissue tumors.
CAESAREA, Israel, Sept. 8,
2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure" or the "Company"), developer of the
ProSense® System, a minimally-invasive cryoablation technology
that destroys tumors by freezing as an alternative to surgical
tumor removal, today announced it will participate in the
Cardiovascular and Interventional Radiology Society of Europe (CIRCE) 2023 Annual Congress in
Copenhagen, Denmark on
September 9 – 13, 2023. IceCure will
exhibit ProSense and provide hands-on demonstrations at booth #D56.
Additional high-profile events include:
IceCure Symposium at CIRSE 2023
Monday, September 11
14:30 – 15:30 CEST
Location: Auditorium 10
Professor Julien Frandon, MD, PhD
of CHU de Nîmes and Professor Francois
Cornelis, MD, PhD will moderate our symposium titled
"Cryoablation using a liquid nitrogen, single probe system: from
simple to complex cases". The presentation will include:
- A brief overview of the advantages of liquid nitrogen based
cryoablation systems by Professor Julien
Frandon
- Pushing the limits of LN2 cryoablation: From the breast to ENT
and everything in between by Professor Julien Frandon
- From desmoid tumors to endometriosis: a fifteen-year experience
of cryoablation of soft tissue masses by Professor Francois Cornelis
The presentations will be followed by a Q&A session. The
symposium will be broadcast live on the CIRSE event website. Anyone
can watch it by logging in or registering for a free myCIRSE
account. Within the first 24 hours after the live session, the
on-demand content will be available on CIRSE.
CIRCE 2023 Hands-On Tumor Ablation
Monday, September 11
16:15 – 17:45 CEST
Location: HDT-TA 3
IceCure will be participating in the Tumor Ablation Hands-On
Device Training with the ProSense cryoablation system. This is a
great opportunity for attendees to gain hands-on knowledge of
IceCure's cryoablation device and to see the system's advantages.
To learn more, visit CIRSE 2023 on how to participate.
Women in IR Grant
IceCure is proud to sponsor CIRSE's "Supporting Women in IR
Grant" to encourage participation by women in interventional
radiology for submitting abstracts to the conference. Thanks to
this grant, ten aspiring women interventional radiologists'
abstracts were accepted and will receive sponsored congress
registration, travel, and accommodation.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses the
expected results of its "Supporting Women in IR Grant" and its
upcoming participation in the Cardiovascular and Interventional
Radiology Society of Europe, which
will include conducting its own symposium, exhibiting ProSense, and
providing hands-on demonstrations through the Tumor Ablation
Hands-On Device Training. Because such statements deal with future
events and are based on IceCure's current expectations, they are
subject to various risks and uncertainties and actual results,
performance, or achievements of IceCure could differ materially
from those described in or implied by the statements in this press
release. The forward-looking statements contained or implied in
this press release are subject to other risks and uncertainties,
many of which are beyond the control of the Company, including
those set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on
March 29, 2023, and other documents
filed with or furnished to the SEC which are available on the
SEC's website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
Logo -
https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-to-join-hands-on-cryoablation-session-with-prosense-and-host-symposium-led-by-renowned-doctors-at-the-circe-2023-annual-congress-301921821.html
SOURCE IceCure Medical